Speakers: Prof. Steven Petrou, Director of the Florey and RogCon, Chief Scientific Officer, and Dr. Kiran Reddy, CEO of Praxis Precision Medicines.

At the 2018 American Epilepsy Society meeting, Prof Petrou presented results from a mouse model of an antisense oligonucleotide (ASO) treatment for SCN2A epilepsies developed by RogCon. Praxis Precision Medicines has joined with RogCon to advance that treatment program (RC-222).

In this webinar, Prof Petrou will discuss his ASO research in SCN2A as well as talk about what ASOs are and their safety. Kiran Reddy will discuss the process of taking an ASO from the laboratory to clinical trials, the steps involved in that process, and how the process can be sped up and facilitated by the SCN2A community.